Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

Oncology Group ◽

Open Label ◽

Phase 3 ◽

Oncology Group Study ◽

Phase II Evaluation of 24-h Continuous Infusion Topotecan in Recurrent, Potentially Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.2000.5755 ◽

2000 ◽

Vol 77 (1) ◽

pp. 112-115 ◽

Cited By ~ 30

Author(s):

Maurie Markman ◽

John A. Blessing ◽

Ronald D. Alvarez ◽

Parviz Hanjani ◽

Steven Waggoner ◽

...

Keyword(s):

Ovarian Cancer ◽

Continuous Infusion ◽

Phase Ii ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052)

Journal of Gynecologic Oncology ◽

10.3802/jgo.2021.32.e90 ◽

2021 ◽

Vol 32 ◽

Author(s):

Se Ik Kim ◽

Jeong-Won Lee ◽

Kidong Kim ◽

Maria Lee ◽

Jigeun Yoo ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Survival Outcomes ◽

Oncology Group ◽

Oncology Group Study ◽

Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.2001.6441 ◽

2002 ◽

Vol 84 (1) ◽

pp. 32-35 ◽

Cited By ~ 9

Author(s):

Steven C. Plaxe ◽

John A. Blessing ◽

Michael A. Bookman ◽

William T. Creasman

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2007.11.029 ◽

2008 ◽

Vol 108 (3) ◽

pp. 493-499 ◽

Cited By ~ 90

Author(s):

Angeles Alvarez Secord ◽

John A. Blessing ◽

Deborah K. Armstrong ◽

William H. Rodgers ◽

Zoe Miner ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Growth Factor Receptor ◽

Receptor Expression ◽

Oncology Group ◽

Oncology Group Study ◽

Platinum Sensitive ◽

Epidermal Growth

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial

Journal of Gynecologic Oncology ◽

10.3802/jgo.2022.33.e12 ◽

2022 ◽

Vol 33 ◽

Author(s):

Junsik Park ◽

Myong Cheol Lim ◽

Jae-Kwan Lee ◽

Dae Hoon Jeong ◽

Se Ik Kim ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Phase Ii Study ◽

Parp Inhibitor ◽

Gynecologic Oncology ◽

Recurrent Ovarian Cancer ◽

Oncology Group ◽

Platinum Sensitive ◽

Previously Treated

Maspin expression in epithelial ovarian cancer and associations with poor prognosis: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2006.02.014 ◽

2006 ◽

Vol 101 (3) ◽

pp. 390-397 ◽

Cited By ~ 26

Author(s):

Angeles Alvarez Secord ◽

Paula S. Lee ◽

Kathleen M. Darcy ◽

Laura J. Havrilesky ◽

Lisa A. Grace ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Poor Prognosis ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Maspin Expression

A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2005.09.032 ◽

2006 ◽

Vol 100 (3) ◽

pp. 586-590 ◽

Cited By ~ 20

Author(s):

Allan Covens ◽

John Blessing ◽

David Bender ◽

Robert Mannel ◽

Mark Morgan

Keyword(s):

Phase Ii ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)

BMC Cancer ◽

10.1186/s12885-019-5514-7 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 4

Author(s):

Young Shin Chung ◽

Sang-Yoon Park ◽

Jung-Yun Lee ◽

Jeong-Yeol Park ◽

Jeong-Won Lee ◽

...

Keyword(s):

Ovarian Cancer ◽

Neoadjuvant Chemotherapy ◽

Gynecologic Oncology ◽

Serous Carcinoma ◽

High Grade ◽

Advanced Stage ◽

Oncology Group ◽

Oncology Group Study

An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: A Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION

Annals of Oncology ◽

10.1093/annonc/mdz250.069 ◽

2019 ◽

Vol 30 ◽

pp. v432

Author(s):

J.-Y. Lee ◽

J.W. Kim ◽

B.G. Kim ◽

S. Kim ◽

H.S. Kim ◽

...

Keyword(s):

Ovarian Cancer ◽

Targeted Therapy ◽

Gynecologic Oncology ◽

Recurrent Ovarian Cancer ◽

Oncology Group ◽

Oncology Group Study ◽

Platinum Resistant

An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2004.05.033 ◽

2004 ◽

Vol 94 (2) ◽

pp. 368-374 ◽

Cited By ~ 40

Author(s):

David H Moore ◽

James T Kauderer ◽

Jeffrey Bell ◽

John P Curtin ◽

Linda Van Le

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Gynecologic Oncology ◽

Oncology Group ◽

Alternative Treatments ◽

Oncology Group Study ◽

Factors Influencing